– EBITDA grew 47% for 12 months ended 31 Dec 2021- Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN’s shareholder value- Growth trend in revenue expected to continue as COVID-19 situation in China improves SINGAPORE, Feb 23, 2022 – (ACN Newswire) – Catalist listed Aoxin Q&M Dental Limited (“Aoxin” or “the Group”), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 (“FY2021”). The Group reported a net loss after tax of RMB7.3 million for FY2021, an improvement from the net loss of RMB12.1 million from a year ago. In …
